Product Overview
Tesamorelin is a stabilised analogue of growth hormone releasing hormone, and it is unusual in this catalogue for having a licence. The approved injectable is used for excess visceral fat in patients with lipodystrophy, and that narrow indication is the only population in which the clinical numbers were generated. Generic Peptides offers 2 mg, 5 mg and 10 mg lyophilised vials for laboratory use.
Mechanically it is straightforward. The peptide asks the pituitary for a transient rise in endogenous growth hormone, which lifts IGF-1 as a consequence; it does not introduce hormone from outside. What makes it practical in the clinic is the stabilisation, because unmodified GHRH is destroyed in minutes. Even so, the numbers remain short: the label for the SV form gives an average elimination half-life of about eight minutes once 1.4 mg has been injected under the skin, the WR form about eleven minutes, and general references quote 26 to 38 minutes. That is why the approved schedule is daily rather than weekly, unlike CJC-1295 DAC, a different analogue engineered for a much longer stay in the body.
Two caveats belong up front. The clinical population was people with lipodystrophy, so carrying those findings across to healthy users is an assumption rather than a result. And Sermorelin, the older GHRH fragment, shares the receptor but not the evidence base. In sport the peptide is named directly in class S2 and is prohibited at all times.
Dosage Protocol
The table separates what the licence says from what a research vial can actually deliver. No separate female protocol for this material appears in the sources checked.
| Item | Figure | Basis |
| Approved Egrifta dose | 2 mg daily, subcutaneous | Licensed product |
| Approved Egrifta SV dose | 1.4 mg daily, subcutaneous | Licensed product |
| Vial coverage | A 5 mg vial falls short of one week | Arithmetic at the approved amount |
| Length in clinic | Long term, daily | Consultation of the clinical programme |
| Female | No confirmed protocol | Nothing found outside the licensed population |
Reconstitution arithmetic decides how usable a vial is. One millilitre of bacteriostatic water in the 5 mg vial gives 5 mg per millilitre, where the approved 2 mg amount works out at 0.4 ml, or 40 marks on a U-100 barrel. Two millilitres halves the strength, so 2 mg becomes 0.8 ml. The 2 mg vial at 1 ml gives a single day of the licensed amount, and the 10 mg vial at 2 ml reproduces the middle strength at a lower cost per milligram.
Suggested Protocols
In the clinic this peptide is used alone, every day, for as long as the indication lasts. The combinations below describe how it is read beside other peptides rather than a tested schedule.
Adjacent reading includes HGH Frag 176-191 and Adipotide on the fat-loss shelf, and Somatropin for supplied growth hormone. The clinic did not cycle this peptide on and off the way bodybuilding protocols cycle steroids, so short blocks are a departure from how the data were generated.
What to Expect
- Growth hormone and IGF-1 answer within hours. The rise after an injection is prompt, but it fades fast and needs repeating the next day.
- Visceral fat moves over months. The clinical reduction in deep abdominal fat was recorded with long-term daily use, not with a short block.
- Nothing accumulates. Half-lives of roughly 8 to 38 minutes depending on the form mean the level is back to baseline quickly.
- The evidence comes from one population. Adults with lipodystrophy were studied; healthy users are extrapolation.
- Vial arithmetic is limiting. A 5 mg vial does not stretch to a week at the licensed amount, which is a practical constraint rather than a question of potency.
- Class reactions still apply. Fluid retention, joint aches and injection site effects are described for growth hormone peptides as a group.
- Doping status is absolute. Class S2 names the compound directly and applies at all times.
Side Effects and Management
What is reported is mostly local and metabolic rather than dramatic, and the clinical programme monitored glucose because of the growth hormone route.
Post-Cycle Therapy (SERM Protocol Not Applicable)
There is nothing to restart. The peptide raises endogenous growth hormone and leaves the gonadal axis alone, so tamoxifen, clomiphene and hCG have no role, and the clinical material contains no withdrawal protocol of that kind.
Keep the powder refrigerated and dark, and hold the mixed solution in the fridge without freezing it. The consumer shelf life of these specific vials after dilution has not been confirmed.
